» Articles » PMID: 6662183

Beta-blocking and Electrophysiological Effects of Propafenone in Volunteers

Overview
Specialty Pharmacology
Date 1983 Jan 1
PMID 6662183
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The chemical structure of propafenone (P) and certain experimental findings suggest that this antiarrhythmic compound could possess beta-blocking properties. To evaluate the clinical relevance of the latter cardiovascular effects of P during exercise were studied. After oral administration of P 150 and 300 mg in solution, six healthy volunteers were subjected to graded exercise. These doses of P, which are usually effective against arrhythmias, decreased exercise-induced tachycardia, whereas the systolic blood pressure was lowered but only at rest, and the diastolic pressure was slightly raised. However, taking into account dose ratio, and the intensity and duration of the reduction in exercise tachycardia, this effect of P was only about 5% at its maximum compared to propranolol and similar active beta-blocking compounds. The reduction in heart rate produced by P was not correlated with the plasma level nor did it show dose dependency, in contrast to beta-blocking agents, and also in contrast to its electrophysiological effects on the PQ interval.

Citing Articles

Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Harron D, Brogden R Drugs. 1987; 34(6):617-47.

PMID: 3322781 DOI: 10.2165/00003495-198734060-00001.


Clinical pharmacokinetics of propafenone.

Hii J, Duff H, Burgess E Clin Pharmacokinet. 1991; 21(1):1-10.

PMID: 1914339 DOI: 10.2165/00003088-199121010-00001.


Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.

Zehender M, Hohnloser S, Geibel A, Furtwangler A, Olschewski M, Meinertz T Br Heart J. 1992; 67(6):491-7.

PMID: 1622701 PMC: 1024894. DOI: 10.1136/hrt.67.6.491.


Stereoselective electrophysiological effects of propafenone in Langendorff perfused guinea pig hearts.

Stark U, Stark G, Stoschitzky K, Pilger E, Nagl S, Lindner W Basic Res Cardiol. 1992; 87(1):87-97.

PMID: 1567355 DOI: 10.1007/BF00795393.


The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.

Groschner K, Lindner W, Schnedl H, Kukovetz W Br J Pharmacol. 1991; 102(3):669-74.

PMID: 1364837 PMC: 1917929. DOI: 10.1111/j.1476-5381.1991.tb12231.x.

References
1.
HAPKE H, Prigge E . [Pharmacology of 2'-[2-hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophenone (Propafenone, SA 79)-hydrochloride]. Arzneimittelforschung. 1976; 26(10):1849-57. View

2.
Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A . Electrophysiological and antiarrhythmic properties of propafenon in isolated cardiac preparations. J Cardiovasc Pharmacol. 1981; 3(6):1162-73. DOI: 10.1097/00005344-198111000-00002. View

3.
Beck O, Witt E, HOCHREIN H . [Effect of the antiarrhythmic agent propaphenone on cardiac conduction. clinical studies using bundle of his electrography]. Z Kardiol. 1975; 64(2):179-87. View

4.
Richards D, Woodings E, Maconochie J . Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol. 1977; 4(1):15-21. PMC: 1428991. DOI: 10.1111/j.1365-2125.1977.tb00660.x. View

5.
Blanke H, Aschbrenner B, Karsch K, Kreuzer H . [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)]. Dtsch Med Wochenschr. 1979; 104(16):587-91. DOI: 10.1055/s-0028-1103950. View